ARCA biopharma
Personalized therapies for cardiovascular disease through advanced genetic research
Personalized therapies for cardiovascular disease through advanced genetic research
ARCA biopharma is a Colorado-based biopharmaceutical company that was founded in 1992. The company's slogan, "Personalized therapies for cardiovascular disease through advanced genetic research," reflects its core focus on developing genetically-targeted therapies for cardiovascular diseases. By integrating expertise in cardiovascular pathophysiology, molecular genetics, and clinical development, ARCA aims to create personalized treatments for cardiovascular disease using genetic information. The company received a significant $51.65MPost-IPO Equity investment on 25 June 2015, with participation from notable investors such as New Enterprise Associates, RA Capital Management, Venrock, Franklin Templeton, and Tekla Capital Management. This investment underscores the market's confidence in ARCA's innovative approach to addressing cardiovascular diseases through advanced genetic research. As the biotechnology industry continues to advance, ARCA biopharma's focus on personalized therapies positions the company at the forefront of genetically-targeted treatments for cardiovascular diseases. With substantial backing from experienced investors, ARCA is well-positioned to advance its mission of leveraging genetic information to develop innovative solutions for cardiovascular health.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $51.65M | 5 |
|
25 Jun 2015 |
| Post-IPO Equity | $1.25M | - | 17 Jun 2013 | |
| Post-IPO Equity | $4.55M | - | 05 Jan 2012 | |
| Series B | $18.00M | 5 |
|
12 Jun 2007 |
| Series A | $15.00M | - | 03 Mar 2006 |
No recent news or press coverage available for ARCA biopharma.
We care about your data, and we'd love to use cookies make your experience better.
